BlackRock’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-39,425
| Closed | -$800K | – | 5790 |
|
|
2022
Q4 | $800K | Sell |
39,425
-497
| -1% | -$7.62K | ﹤0.01% | 4479 |
|
|
2022
Q3 | $429K | Buy |
39,922
+127
| +0.3% | +$1.44K | ﹤0.01% | 4769 |
|
|
2022
Q2 | $477K | Buy |
39,795
+4,472
| +13% | +$72.1K | ﹤0.01% | 4785 |
|
|
2022
Q1 | $756K | Buy |
35,323
+579
| +2% | +$15.3K | ﹤0.01% | 4761 |
|
|
2021
Q4 | $1.17M | Buy |
34,744
+10,058
| +41% | +$280K | ﹤0.01% | 4619 |
|
|
2021
Q3 | $635K | Buy |
24,686
+12,774
| +107% | +$228K | ﹤0.01% | 4694 |
|
|
2021
Q2 | $160K | Sell |
11,912
-17,350
| -59% | -$214K | ﹤0.01% | 4945 |
|
|
2021
Q1 | $312K | Sell |
29,262
-725
| -2% | -$8.27K | ﹤0.01% | 4669 |
|
|
2020
Q4 | $241K | Buy |
29,987
+496
| +2% | +$3.9K | ﹤0.01% | 4452 |
|
|
2020
Q3 | $220K | Buy |
29,491
+8,948
| +44% | +$79.4K | ﹤0.01% | 4393 |
|
|
2020
Q2 | $186K | Sell |
20,543
-184
| -0.9% | -$1.91K | ﹤0.01% | 4380 |
|
|
2020
Q1 | $199K | Sell |
20,727
-5,983
| -22% | -$71.6K | ﹤0.01% | 4231 |
|
|
2019
Q4 | $385K | Buy |
26,710
+6,142
| +30% | +$89.5K | ﹤0.01% | 4205 |
|
|
2019
Q3 | $309K | Sell |
20,568
-224
| -1% | -$3.12K | ﹤0.01% | 4254 |
|
|
2019
Q2 | $276K | Buy |
20,792
+10,045
| +93% | +$122K | ﹤0.01% | 4306 |
|
|
2019
Q1 | $141K | Buy |
10,747
+488
| +5% | +$7.11K | ﹤0.01% | 4316 |
|
|
2018
Q4 | $149K | Buy |
10,259
+3,137
| +44% | +$51.2K | ﹤0.01% | 4279 |
|
|
2018
Q3 | $127K | Buy |
7,122
+388
| +6% | +$6.72K | ﹤0.01% | 4414 |
|
|
2018
Q2 | $97K | Buy |
+6,734
| New | +$118K | ﹤0.01% | 4465 |
|
BlackRock's OPNT Position: Q1 2023 in Review
BlackRock sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 39,425 shares — an estimated $800K sold.
BlackRock first reported a position in OPNT in Q2 2018 and held it in 19 quarters. The position peaked at $1.17M in Q4 2021. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.
- BlackRock reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- BlackRock sold 39,425 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $800K.
- BlackRock first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 19 quarters.
- BlackRock's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $1.17M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.